Vimarsana
Biggest News Aggregation in the World

Page 6 - Deepmatter Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Deepmatter Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Deepmatter Group Today - Breaking & Trending Today

Kazera Global PLC slides as impact of Covid-19 causes delay in publication of annual results - Vimarsana News

Kazera Global PLC slides as impact of Covid-19 causes delay in publication of annual results

A look at some of the major movers in London on Christmas Eve

IN BRIEF: DeepMatter in talks to secure - Vimarsana News

IN BRIEF: DeepMatter in talks to secure

IN BRIEF: DeepMatter in talks to secure

Source: lse.co.uk
Investegate |DeepMatter Group PLC Announcements | DeepMatter Group PLC: DigitalGlassware platform trial with Aurigene - Vimarsana News

Investegate |DeepMatter Group PLC Announcements | DeepMatter Group PLC: DigitalGlassware platform trial with Aurigene

Investegate announcements from DeepMatter Group PLC, DigitalGlassware� platform trial with Aurigene

Glasgow's DeepMatter hails Dr Reddy, India, contract - Vimarsana News

Glasgow's DeepMatter hails Dr Reddy, India, contract

DEEPMATTER, the digital chemistry specialist, has signed a contract with a major pharmaceuticals manufacturer in India to provide its real-time…

Chemistry-focused tech specialist DeepMatter Group sees revenues jump - Vimarsana News

Chemistry-focused tech specialist DeepMatter Group sees revenues jump

The firm says half of the world’s top ten pharmaceutical organisations use its products. Picture: contributed. Aim-quoted DeepMatter also in the year saw a 300 per cent jump in the number of trials of its products, while user numbers leapt by nearly a fifth. Chief executive Mark Warne said: "I am pleased to report that we achieved notable strategic successes and have entered 2021 in a strong position despite the uncertainty created in 2020 by the impact of Covid-19. "We will continue to build on the momentum of the second half of 2020 in the current year with sales to the pharmaceutical i...